MiMedx: Q3 Earnings Snapshot

MiMedx Group Inc. (MDXG) reported a Q3 loss of $8.7 million, or 6 cents per share, with adjusted losses of 1 cent per share. Revenue was $62.3 million. The company expects full-year revenue between $250 million and $260 million, according to its earnings release.

Original reporting
Published Oct 28, 2026, 8:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MiMedx: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$MDXGBearishMed
01

Why it matters

Earnings miss and modest guidance suggest near‑term weakness, but the company's niche market may offer longer‑term upside if pipeline advances.

02

Market read

Primary earnings release for a small‑cap biotech; new data may drive short‑term price movement.

03

What to watch

Potential cost‑cutting measures or upcoming product launches not disclosed could mitigate downside.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

MiMedx Group Inc. (MDXG) is a developer of biomaterials from human amniotic membrane, listed on Nasdaq.

Company-level read

Ticker impact

$MDXGBearishHigh confidence
Context

MiMedx Group reported Q3 loss of $8.7M, revenue $62.3M and full-year guidance of $250M‑$260M, a fresh earnings disclosure.

Expected impact

downward pressure as investors price in the loss and limited revenue outlook

Evidence & confidence

Earnings miss and cautious guidance for a small‑cap biotech typically trigger sell‑offs in the near term.

Market effects

May dampen sentiment in the regenerative‑medicine and biotech sector.

Limited to U.S. biotech investors; no broader regional effect.

Low global impact given the company's size.

Counterpoint

If the market overreacts to the loss, a short‑term bounce could occur on any positive trial news.

Key entities

  • MiMedx Group Inc.

    Biomaterials developer reporting Q3 results.

Related articles

$MDXGMed

MiMedx Group Inc (MDXG) (Q3 2026) Earnings Call Highlights: Revenue Jumps 36%

MiMedx Group Inc (MDXG) reported a 36% revenue jump in Q3 2026. CFO Danilo D'Alessandro expects gradual reduction in cash burn over the next four to six quarters. CEO Joe Burnett highlighted growth opportunities in spine laser therapy, with estimated revenue of $13,000 to $20,000 per procedure. The company aims for mid-teens growth in 2027, with guidance expected in January. MDXG also discussed investments in robotics and focused ultrasound, and the status of the UniQure AMT-130 BLA submission.

$MDXGMed

MiMedx (MDXG) Q3 2026 Earnings Call Transcript

MiMedx (MDXG) reported Q3 2026 net sales of $62M, with Surgical revenue up 9% YoY and Wound Care Center volume up 7% sequentially. The company expects to complete the Sanara MedTech acquisition, pending FTC approval, aiming for $400M in combined revenue and 20% adjusted EBITDA margin. MiMedx also won a court ruling against the FDA's classification of AXIOFILL and reached a $25M settlement in a patent infringement case.

$MDXGHighAI 8/10

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call

MiMedx Group (MDXG) reported Q3 earnings with gross profit of $50M, down from $95M YoY, and a GAAP net loss of $9M. Wound care volume rose 20% YoY, but margins declined due to pricing and product mix. The company expects 2027 conditions to persist and anticipates modest EBITDA growth in Q4. MiMedx is acquiring Sanara MedTech, facing FTC review, aiming for $400M revenue and 20% EBITDA margin post-merger. Legal and product updates include a $25M settlement and progress on 510(k) submissions.

$MDXGMed

MIMEDX Announces Third Quarter 2026 Operating & Financial Results Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers…

MIMEDX GROUP, INC. (MDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. MIMEDX Announces Third Quarter 2026 Operating & Financial Results Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court Ruling in AXIOFILL®

$SMTIMedAI 8/10

MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months

The FTC issued a Second Request for more information on MiMedx's (MDXG) acquisition of Sanara (SMTI), delaying the merger beyond the year-end target. SMTI shares fell 5.5%, dropping below their 50-day moving average, while MDXG shares declined 2.8%. The deal, valued at $35 per share, aims to create a larger regenerative medicine company with $400M revenue expected in FY2027.